Stay updated with breaking news from Script Biotech. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
/PRNewswire/ -- The "Global Peptide Synthesis Market by Reagent (Resins, Amino Acid, Dyes), Equipment (Peptide Synthesizer, Chromatography, Lyophilizer),...
/PRNewswire/ -- The "Global Peptide Synthesis Market by Reagent (Resins, Amino Acid, Dyes), Equipment (Peptide Synthesizer, Chromatography, Lyophilizer),...
Exclusive agreement for region brings GenScript's innovative cPass™ kit to Spain, Portugal and Andorra LEIDEN, Netherlands & BILBAO, Spain--(BUSINESS WIRE)--GenScript Biotech (Netherlands) BV, a subsidiary of GenScript Biotech Corporation ("GenScript", Stock Code: 1548.HK), a world-leading biotechnology company, and IES Diagnostics, the Life Science division of IES Medical, a company based in Spain, announced they have signed an agreement for the exclusive distribution of the GenScript cPass™ SARS-CoV-2 Neutralization Antibody Detection Kit in Spain, Portugal, and Andorra. The test measur...
Press release content from Business Wire. The AP news staff was not involved in its creation. GenScript Biotech BV and IES Diagnostics Forge Distribution Agreement for SARS-CoV-2 Neutralizing Antibody Kit April 14, 2021 GMT LEIDEN, Netherlands & BILBAO, Spain--(BUSINESS WIRE)--Apr 14, 2021-- ADVERTISEMENT The test measures the presence of neutralizing antibodies (NAbs) in patients recovering from COVID-19 or receiving a vaccine. It is the only U.S. FDA Emergency Use Authorized (EUA) serology test for neutralizing antibodies from recent and prior SARS-CoV-2 infections. The kit is also CE marke...
Share this article Share this article ResearchAndMarkets.com's offering. The global CRISPR gene editing market was valued at $846.2 million in 2019 and is expected to reach $10,825.1 million by 2030, registering a CAGR of 26.86% during the forecast. The development of genome engineering with potential applications proved to reflect a remarkable impact on the future of the healthcare and life science industry. The high efficiency of the CRISPR-Cas9 system has been demonstrated in various studies for genome editing, which resulted in significant investments within the field of genome engineeri...